Search clinical trials for: Non-squamous Non-small Cell Lung Cancer

Total 156350 results

Xencor, Inc.

Recruiting

Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC

Nonsquamous Non-small Cell Lung Cancer

United States
Sung Yong Lee
Yuhan Corporation

Recruiting

A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy (PLATINUM)

Non-small Cell Lung Cancer Stage III | Non-squamous Non-small-cell Lung Cancer | EGFR Positive Non-small Cell Lung Cancer

Korea, Republic of
Regeneron Pharmaceuticals
Sanofi

Active, not recruiting

Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

Non-small Cell Lung Cancer

United States, France, Korea, Republic of, Italy, Austria, China, Georgia, Greece, Ireland, Lithuania, Malaysia, Poland, Romania, Russian Federation, Slovakia, Thailand, Turkey, Ukraine
Celldex Therapeutics
Merck Sharp & Dohme LLC

Completed

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

Melanoma | Follicular Lymphoma | Renal Cell Carcinoma | Breast Cancer | Head and Neck Cancer | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Pancreatic Adenocarcinoma | Ovarian Cancer | Fallopian Tube Cancer | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Non-Hodgkin Lymphoma | ... and other conditions

United States
Seagen Inc.
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of SEA-CD40 Given With Other Drugs in Cancers

Melanoma | Carcinoma, Non-Small- Cell Lung

United States, Canada, Spain, France, Germany, Sweden
Intergroupe Francophone de Cancerologie Thoracique

Completed

Description of Clinical Anatomical Features and Long Term Follow-up for Patients With ALK Rearrangements (CLINALK)

Non-small Cell Lung Cancer | Anaplastic Lymphoma Kinase Gene Mutation

France
Intergroupe Francophone de Cancerologie Thoracique

Completed

Re-introduction of Pemetrexed and Cisplatin With Prolonged Angiogenic Blocking by Bevacizumab in Advanced Lung Cancer. (BUCiL)

Nonsquamous Nonsmall Cell Neoplasm of Lung | Non-small Cell Lung Cancer Metastatic

France
Rain Oncology Inc

Terminated

Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients (TH-4000)

NSCLC | Non-small Cell Lung Cancer | Non-squamous NSCLC

United States, Australia
Xencor, Inc.
ICON plc

Completed

A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors (DUET-2)

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Nasopharyngeal Carcinoma | Small Cell Lung Carcinoma | Hepatocellular Carcinoma | Thymic Carcinoma | Thymoma | Non-small Cell Lung Carcinoma | Mesothelioma | Squamous Cell Carcinoma of the Head and Neck | Cholangiocarcinoma | Breast Carcinoma | Fallopian Tube Carcinoma and other conditions

United States
Regeneron Pharmaceuticals
Sanofi

Terminated

REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer

Non-small Cell Lung Cancer

United States, Italy, Lithuania
AbbVie

Completed

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers

Non-squamous Non-small Cell Lung Cancer

United States, Argentina, Australia, Canada, Czechia, Denmark, Finland, Germany, Hungary, Israel, Japan, Korea, Republic of, Netherlands, New Zealand, Russian Federation, South Africa, Spain, Taiwan, Turkey, United Kingdom
AbbVie

Completed

A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors

Advanced Solid Tumors Cancer

United States, Australia, France, Taiwan
PharmaMar

Completed

Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors

Breast Cancer | Small Cell Lung Cancer | Ovarian Cancer | Non-small Cell Lung Cancer | Head and Neck Carcinoma | Gynecological Cancer | Non-squamous Cell Lung Cancer

United States, Spain, Switzerland
AIO-Studien-gGmbH
AstraZeneca

Terminated

Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB (NeoIntercal)

NSCLC | Non-squamous Non-small Cell Lung Cancer Stage II | Non-squamous Non-small Cell Lung Cancer Stage IIIA | Non-squamous Non-small Cell Lung Cancer Stage IIIB | Activating EGFR Mutation

Germany
University of Athens

Completed

Bevacizumab in Combination With Chemotherapy in Patients With Advanced or Recurrent Non-squamous NSCLC

Non-small Cell Lung Cancer | Unresectable Malignant Neoplasm

Greece
Asan Medical Center
Eli Lilly and Company; Korean Cancer Study Group

Unknown

Pemetrexed With or Without Carboplatin for Elderly Non-squamous Non-small Cell Lung Cancer (ACE)

Non-small Cell Lung Cancer

Korea, Republic of
Henan Cancer Hospital
Kingbio Medical (Beijing) Co., Ltd.

Recruiting

Patient-derived Organoid Drug Sensitivity Guided Treatment for Drug-resistant Recurrent Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Qilu Pharmaceutical Co., Ltd.

Recruiting

A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors

Colorectal Cancer | Pancreatic Cancer | Solid Tumor | Non-small Cell Lung Cancer

China
GlaxoSmithKline

Not yet recruiting

Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Patient-derived Organoids and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)

Lung Cancer, Non-Small Cell

United Kingdom
Changzhou No.2 People's Hospital

Not yet recruiting

FMT+Immunotherapy+Chemotherapy as First-line Treatment for Driver-gene Negative Advanced NSCLC

Non-small Cell Lung Cancer
West China Hospital

Not yet recruiting

Neoadjuvant Chemoimmunotherapy in Stage IIIA- N2IIIB Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Stage IIIB | Non-small Cell Lung Cancer Stage ⅢA
Peking Union Medical College Hospital

Not yet recruiting

ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI

Non-small Cell Lung Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Not yet recruiting

A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Not yet recruiting

A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
AstraZeneca

Not yet recruiting

Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC (FOREFRONT)

Neoplasms | Respiratory Tract Diseases | Lung Diseases | Neoplasms by Site | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms

China
Henan Cancer Hospital
Jiangsu Simcere Pharmaceutical Co., Ltd.

Not yet recruiting

the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib

Non-small Cell Lung Cancer

China
Fudan University

Recruiting

Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC

Non-small Cell Lung Cancer | Neuroendocrine Carcinoma | Histology Transformation

China
Astellas Pharma Inc

Recruiting

A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors

Solid Tumor

United States
Tianjin Medical University Cancer Institute and...

Recruiting

Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

Non-small Cell Lung Cancer | EGFR Activating Mutation | EGFR-TKI Resistant Mutation | Cell Cycle Deregulation

China
AstraZeneca
Daiichi Sankyo

Not yet recruiting

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (TROPION-Lung10)

Non-Small Cell Lung Cancer

Italy, Spain, Poland, Canada, Korea, Republic of, Hungary, Turkey, Taiwan, United Kingdom, Japan, Austria, Australia, Germany, Brazil
Shanghai Chest Hospital

Recruiting

Predicting Non-small Cell Lung Cancer (NSCLC) Lymph Node Metastasis: Integrating Circulating Tumor DNA (ctDNA) Mutation/ Methylation Profiling With Positron Emission Tomography-computed Tomography (PET-CT) Scan

Carcinoma | Non-small Cell Lung Cancer

China
The Affiliated Hospital of Qingdao University

Recruiting

Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer (PILOT)

Non-small-cell Lung Cancer (NSCLC)

China
Hunan Province Tumor Hospital

Not yet recruiting

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW (WUKONG-32-RW)

Non-small Cell Lung Cancer

China
Fudan University

Recruiting

Survival Validation and Gene Mutations of N Descriptors in the Ninth Edition of the TNM Classification for Lung Cancer

Non-small Cell Lung Cancer

China
AstraZeneca
Daiichi Sankyo

Not yet recruiting

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer (TROPION-Lung14)

Non-small Cell Lung Cancer

China, Taiwan, Korea, Republic of, Australia
Samsung Bioepis Co., Ltd.

Recruiting

A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Stage IV

Georgia, India, Romania, Spain
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004)

Non-small Cell Lung Cancer

United States
European Institute of Oncology
University of Rome Tor Vergata

Recruiting

Volatolomic and Proteomic Profile for Early Diagnosis of Lung Cancer

Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage II | Lung Cancer Diagnosis

Italy
Guangzhou Institute of Respiratory Disease

Recruiting

To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

China
TheRas, Inc

Recruiting

Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

NSCLC | Metastatic Lung Cancer | Non-small Cell Lung Cancer | Advanced Lung Carcinoma | Metastatic Non-Small Cell Lung Cancer | KRAS G12C

United States, Australia
The First Affiliated Hospital of Zhengzhou University

Recruiting

Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Shanghai Shengdi Pharmaceutical Co., Ltd

Not yet recruiting

A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients

Non-squamous Non-small Cell Lung Cancer

China
LG Chem

Not yet recruiting

Study to Evaluate LB-LR1109 for the Treatment of Solid Tumors (LB-LR1109)

Urothelial Carcinoma | Malignant Melanoma | Non-small Cell Lung Cancer(NSCLC) | Head and Neck Squamous Cell Carcinoma(HNSCC) | Renal Cell Carcinoma(RCC)
Amgen

Recruiting

AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)

Non-small Cell Lung Cancer | Thoracic Tumors

United States
Samsung Medical Center
Memorial Sloan Kettering Cancer Center; Mayo Clinic; Yale University; All India... and other collaborators

Not yet recruiting

Anesthesia and Non-small Cell Lung Cancer Recurrence (GASTIVA)

Surgery | Non-small Cell Lung Cancer | Anesthesia
Marc de Perrot
Ozmosis Research Inc.

Not yet recruiting

Treatment of Pulmonary SUlcus, Pancoast and Chest Wall Non-small Cell Lung Cancer Employing Radiation, Immuno-oncology and Resection (SUPER)

Non-small Cell Lung Cancer (NSCLC) | Lung Cancer Patients
Guangzhou Institute of Respiratory Disease

Recruiting

A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Daiichi Sankyo
Merck Sharp & Dohme LLC

Recruiting

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXD) In Subjects With Recurrent Or Metastatic Solid Tumors

Recurrent or Metastatic Solid Tumors

United States
GlaxoSmithKline

Recruiting

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Neoplasms

United States, Spain, Korea, Republic of
Immune Oncology Research Institute
Agenus Inc.

Not yet recruiting

Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008)

Non-small Cell Lung Cancer

Armenia

Search clinical trials for: Non-squamous Non-small Cell Lung Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations